Clinical Genomics Appoints Roger Moody as Chief Financial Officer

BRIDGEWATER, N.J. – November 28, 2017

Clinical Genomics, a leading provider of cancer testing solutions, today announced the appointment of Roger Moody as Chief Financial Officer. Moody is a life sciences industry expert with a proven track record in leading finance and operations for rapidly growing companies.

“We are thrilled to welcome Roger to our leadership team. His well-rounded executive experience will be a tremendous asset to Clinical Genomics as we enter our most important growth phase to date. We firmly believe that Roger will be key in executing on the mission and long-term value we are building,” said Lawrence LaPointe, PhD, CEO of Clinical Genomics.

Prior to joining Clinical Genomics, Moody served as Chief Executive Officer of GlySure Limited, a leading UK-based company specializing in continuous glucose monitoring (CGM). Prior to GlySure, Moody held several leadership positions including the role of Chief Financial Officer at Nanosphere, Inc. He also served as Chief Financial Officer at Medsn, Inc. prior to becoming the Executive Vice President, Managing Director and then Chief Operating Officer following its sale to Indegene.

Moody earned a Bachelor of Science in Finance from Syracuse University and a Master of Business Administration with an emphasis in Finance from the Graduate School of Business at the University of Chicago.

About Clinical Genomics

Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, to COLVERA™, a proprietary blood test identifying circulating tumor DNA in patient’s post-treatment for early detection of recurrence and residual disease. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.

For more information, please visit and